TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05456022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin chemotherapeutic drug as a positive control
Description: Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
Study: NCT05328115

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injections of adjuvanted placebo.
Study: NCT06476964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsies
Description: Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsies
Description: Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsies
Description: Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsies
Description: Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
Study: NCT05122143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)
Study: NCT05674903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum stimulation with Diadem prototype
Description: Diadem prototype device delivers focused low-intensity ultrasound stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation with Diadem prototype
Description: Diadem prototype device delivers active sham, unfocused low-intensity ultrasound stimulation
Study: NCT06555432

Intervention type: DRUG
Intervention: LIVTENCITY
Description: LIVTENCITY tablet.
Study: NCT06187675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Lifestyle Intervention Program
Description: Nutrition and Exercise components for pregnancy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise Lifestyle Intervention Program
Description: Nutrition and Exercise components for pregnancy
Study: NCT06495970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gradient Denervation System
Description: The Gradient Denervation System delivers ultrasound ablation to planned locations in the pulmonary artery to down-regulate the sympathetic nervous drive. The system includes a sterile, single-use catheter that is designed to centrally position the transducer within the arterial target zone for consistency of ablation.
Study: NCT05275049

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT plus translingual stimulation device
Description: PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PT plus translingual stimulation control device
Description: Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
Study: NCT05971524

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6-BT
Description: 2,4 or 8mg of 6-BT once daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6-BT
Description: 2,4 or 8mg of 6-BT once daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6-BT
Description: 2,4 or 8mg of 6-BT once daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule once daily for 4 weeks
Study: NCT06443697

Intervention type: OTHER
Intervention: No intervention
Description: This is a secondary analysis and no intervention is implemented.
Study: NCT06398808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm1
Description: ZYIL1 capsules 25 mg for oral administration + 50 mg placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2
Description: ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
Study: NCT05650528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QG101-23-0 capsules
Description: Single and Multiple Dose for oral
Study: NCT01733134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patient in the placebo group will receive tolvaptan in addition to standard therapy
Study: NCT04833205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
Study: NCT06148766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Health Eternal Renewal Regenerating Face Cream with Royal Jelly and Bee Venom
Description: Face cream containing manuka honey, royal bee jelly, and bee venom.
Study: NCT05122143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: No treatment
Study: NCT05244421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Services
Description: Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.
Study: NCT06321159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: mobile application for diet, exercises and medication adherence
Study: NCT06046872

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Report-back training
Description: Researchers participate in a report-back training program to evaluate potential impacts on knowledge and future behaviors with respect to sharing personal exposure results with study participants.
Study: NCT05990881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: Patients in this group will receive an injection of Botulinum toxin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care corticosteroid injections
Description: Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.
Study: NCT05634889

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalation
Description: No regional radiotherapy. Radiotherapy is given to the remaining breast after breast conserving surgery. Chest wall radiotherapy after mastectomy only in case of wide spread multifocality.
Study: NCT05123274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Mobilization
Description: Five main sessions and two booster sessions focused on providing accurate information about HIV medical care, increasing participants' feelings of resilience and self-worth, and mobilizing or creating social supports.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Care Counseling
Description: Twenty-minute individual counseling session focused on HIV medical care
Study: NCT05211830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXR1096 cream
Description: Skin cream to be applied twice a day to a predefined area of the skin
Study: NCT05650528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QG101-23-0 capsules
Description: Single and Multiple Dose for oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QG101-23-0 capsules
Description: Single and Multiple Dose for oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single and Multiple Dose for oral
Study: NCT05211830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Skin cream to be applied twice a day to a predefined area of the skin
Study: NCT05650528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single and Multiple Dose for oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single and Multiple Dose for oral
Study: NCT05485831

Intervention type: DRUG
Intervention: Epidiolex 100 mg/mL Oral Solution
Description: As prescribed in routine clinical practice in Italy.
Study: NCT05035511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
Study: NCT05122143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: No treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: No treatment
Study: NCT06537466

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Ketogenic Diet
Description: The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
Study: NCT05704699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTRE
Description: eating between 0800h and 1600h daily
Study: NCT06465108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109
Description: Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109
Description: Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 2109
Description: Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied in 1.4 mL water for injection
Study: NCT06568081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SloMo
Description: SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face sessions, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.
Study: NCT06047886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of CD34 selected hematopoietic stem cells
Description: CD34 stem cell isolation and infusion to reduce alloreactive complication of stem cell infusion
Study: NCT06441955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-Boosted Nirmatrelvir (Paxlovid)
Description: Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-Boosted Nirmatrelvir (Paxlovid)
Description: Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Physiological Evaluation
Description: Common Medical laboratory work-up, Cancer screening test, Biomarkers, tissue biopsy, blood specimen, diagnostic imagining, Sensitivity and Specificity, HIV PCR, Viral load ( antigen), CD4- T cell count, while implementation of social mediators of prevention, promotion studies and conceptual models and quality of care.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Physiological Evaluation
Description: Common Medical laboratory work-up, Cancer screening test, Biomarkers, tissue biopsy, blood specimen, diagnostic imagining, Sensitivity and Specificity, HIV PCR, Viral load ( antigen), CD4- T cell count, while implementation of social mediators of prevention, promotion studies and conceptual models and quality of care.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna COVID-19 Vaccine
Description: Single dose, 0.25 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna COVID-19 Vaccine
Description: Single dose, 0.25 mL If previously vaccinated, ≥2 months after receipt of the last previous dose of COVID-19 vaccine
Study: NCT05704699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eTRE with BISC
Description: eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
Study: NCT05235828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Description: This is the experimental arm of the study, where participants will be trained in a form of breathing based meditation that incorporates different breathing techniques centred around controlling arousal and attention. Participants will be encouraged to learn all of the techniques that are covered during these sessions and also utilize the techniques that are most appropriate for their personal needs. After some initial training sessions, participants will be encouraged to practice their new SKY techniques in environments and situations that they have been avoiding. They would begin with situations that are less triggering, and progress to more difficult situations. At each group session, participants will describe their experiences and discuss ways to continue to incorporate the SKY techniques into their daily lives, until it reaches a point of being natural to use these skills throughout the day, both in practice, and in application.
Study: NCT06549816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.
Study: NCT05792345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Thoracic Muscle Plane Block
Description: The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
Study: NCT06441955

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychological
Description: Diagnosis of developmental milestones is considered a missing element in care measurement or a determining factor in disease signs and symptoms in chronic care management. Cognitive mapping, variations of survey, assessments, cancer counseling, leading to the realization that adherence requires a whole-person approach to delivering high-quality and cost-effective care. the project aims to offer opportunities to individuals from diverse backgrounds, including those underrepresented in biomedical research, in an inclusive environment in which all trainees can contribute. The proposed training activities are designed to improve the research skills of the participants and encourage them to pursue further training and careers in biomedical and/or social/behavioral research.
Study: NCT05792345

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: Infiltration by surgeon
Study: NCT06370663

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy + Hepatic Arterial Infusion Chemotherapy (Gesitabine) + Chemotherapy (GEMOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC (GEMOX)
Description: Hepatic Arterial Infusion Chemotherapy (GEMOX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (Gesitabine)
Study: NCT06458595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH658
Description: KH658 Ophthalmic Injection
Study: NCT05617794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion Optics Technology (DOT) Pattern Spectacle Lens
Description: DOT Pattern Spectacle Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Spectacle Lens
Description: Control Spectacles
Study: NCT05652283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles
Study: NCT05946746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PeptiStrong
Description: PeptiStrong is a protein hydrolysate derived from Vicia faba. It is a free-flowing powder, pale yellow in colour. For the purposes of the trial, PeptiStrong will be encapsulated in size '00' hydroxypropyl methylcellulose capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SMCC silicated micro-crystalline cellulose
Description: Placebo - SMCC silicated microcrystalline cellulose (INCI name: MCC, cellulose gel), For the purposes of the trial, SMCC will be encapsulated in size '00' hydropropyl methylcellulose.
Study: NCT04975165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
Study: NCT05242367

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modius Spero active device
Description: Battery powered non-invasive neurostimulation device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Placebo comparator sham device (no active stimulation)
Study: NCT05975996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide added to standard immunosuppressive therapy with herombopag
Description: Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
Study: NCT06393608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epsom salt
Description: Epsom salt solution in water, 25% concentration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water
Study: NCT06161506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elidah Device
Description: The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.
Study: NCT06528132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) (enhanced with peer supporters)
Description: Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders. On-site support and regular follow-up by peer supporters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: social worker-led MBI (without peer supporters)
Description: Mindfulness-based intervention combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.